ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

ClinicalTrials.gov ID: NCT03829657

Public ClinicalTrials.gov record NCT03829657. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Study identification

NCT ID
NCT03829657
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Theravance Biopharma
Industry
Enrollment
203 participants

Conditions and interventions

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 21, 2019
Primary completion
Nov 9, 2021
Completion
Nov 9, 2021
Last update posted
Jan 19, 2023

2019 – 2021

United States locations

U.S. sites
20
U.S. states
15
U.S. cities
19
Facility City State ZIP Site status
Banner Sun Health Research Institute Sun City Arizona 85351
UC San Diego Movement Disorder Center La Jolla California 92307
Stanford Neuroscience Health Center Palo Alto California 94304
Colorado Springs Neurological Associates, PC Colorado Springs Colorado 80907
Parkinson's Disease and Movement Disorders Center Boca Raton Florida 33486
SFM Clinical Research, LLC Boca Raton Florida 33487
Neurostudies, Inc Port Charlotte Florida 33952
Rush University Medical Center Chicago Illinois 60612
NorthShore University Health System Glenview Illinois 60026
University of Kansas Medical Center Research Institute, Inc. Kansas City Kansas 66160
Mayo Clinic Rochester Minnesota 55905
New York University Langone Health New York New York 10016
Wake Forest University Baptist Health Sciences Winston-Salem North Carolina 27157
University of Cincinnati Medical Center (UCGNI) Cincinnati Ohio 45219
Ohio State University - Wexner Medical Center Columbus Ohio 43210
Oregon Health & Science University Portland Oregon 97239
Vanderbilt University Medical Center Nashville Tennessee 37232
University of Texas Southwestern Medical Center Dallas Texas 75390
Georgetown University Hospital McLean Virginia 22101
Inland Northwest Research Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03829657, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2023 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03829657 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →